Literature DB >> 7417084

Irradiation of choroidal melanoma with iodine 125 ophthalmic plaque.

S Packer, M Rotman, R G Fairchild, D M Albert, H L Atkins, B Chan.   

Abstract

Radioactive iodine 125 is a low-energy gamma isotope with physical characteristics suitable for irradiation of intraocular tumors. Metal ophthalmic applicators have been designed to shield vital ocular structures while allowing irradiation of the tumor. We compared the radiation effects of iodine 125 and cobalt 60. The Greene melanoma was transplanted into the suprachoroidal space of rabbits. The tumor then grew as an intraocular mass, was irradiated, and was followed up for two months before enucleation. Histopathologic examination defined the extent of the radiation damage to the tumor and other ocular structures from the iodine 125 and from the cobalt 60. The eye irradiated with iodine 125 suffered minimal radiation damage, whereas the tumor was sterilized. The eye irradiated with cobalt 60 showed substantial radiation damage, and the melanoma was incompletely treated. Our results support the use of iodine 125 in treating intraocular tumors. More research is needed as to optimum total dose and dose rate.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7417084     DOI: 10.1001/archopht.1980.01020040305019

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  10 in total

1.  Experimental study on the fractionation schedule for proton irradiation of uveal melanoma.

Authors:  G Wollensak; L Zografos; C Perret; E Egger; H Fritz-Niggli
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

2.  Improved iodine-125 plaque design in the treatment of choroidal malignant melanoma.

Authors:  J C Hill; R Sealy; D Shackleton; C Stannard; J Korrubel; E Hering; C Loxton
Journal:  Br J Ophthalmol       Date:  1992-02       Impact factor: 4.638

3.  Radioactive iodine-125 as a therapeutic radiation source for management of intraocular tumors.

Authors:  D M Robertson; K S Fountain; J A Anderson; G W Posthumus
Journal:  Trans Am Ophthalmol Soc       Date:  1981

4.  Histopathology studies in human malignant melanomas of the choroid after unsuccessful treatment with 106Ru/106Rh ophthalmic applicators.

Authors:  H Klaus; P K Lommatzsch; U Fuchs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

5.  Treatment of juxtapapillary melanomas.

Authors:  P K Lommatzsch; R Lommatzsch
Journal:  Br J Ophthalmol       Date:  1991-12       Impact factor: 4.638

Review 6.  Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose.

Authors:  Jose J Echegaray; Nikolaos E Bechrakis; Nakul Singh; Claudine Bellerive; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2017-02-08

7.  Magnetic resonance imaging of juxtapapillary plaques in cadaver eyes.

Authors:  D F Williams; W F Mieler; G J Jaffe; D M Robertson; L Hendrix
Journal:  Br J Ophthalmol       Date:  1990-01       Impact factor: 4.638

8.  106Ru/106Rh plaque radiotherapy for malignant melanomas of the choroid. With follow-up results more than 5 years.

Authors:  P K Lommatzsch; I H Kirsch
Journal:  Doc Ophthalmol       Date:  1988 Mar-Apr       Impact factor: 2.379

9.  Feasibility study of a non-invasive eye fixation and monitoring device using a right-angle prism mirror for intensity-modulated radiotherapy for choroidal melanoma.

Authors:  Toshihiko Inoue; Norihisa Masai; Hiroya Shiomi; Ryoong-Jin Oh; Kenji Uemoto; Noriyasu Hashida
Journal:  J Radiat Res       Date:  2017-05-01       Impact factor: 2.724

10.  Adaptive replanning intensity-modulated radiotherapy for choroidal metastasis of breast cancer using optical coherence tomography.

Authors:  Toshihiko Inoue; Norihisa Masai; Ryoong-Jin Oh; Hiroya Shiomi; Noriyasu Hashida
Journal:  J Radiat Res       Date:  2014-04-04       Impact factor: 2.724

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.